Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1 Antibodies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06787183
What this trial is testing

SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases

Who this might be right for
Locally Advanced Rectal Cancer With Liver Metastases
Fujian Cancer Hospital 42
Large-scale testing (Phase 3)Not Yet RecruitingNCT07677293
What this trial is testing

Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases

Who this might be right for
Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Peking University 332
Testing effectiveness (Phase 2)Study completedNCT03021993
What this trial is testing

Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer

Who this might be right for
Oral Cavity SCC
Medical University of South Carolina 17
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07053332
What this trial is testing

A Study on Immunotherapy Combined With Radiotherapy for Esophagogastric Junction/Gastric Adenocarcinoma

Who this might be right for
Esophagogastric Junction/Gastric Adenocarcinoma
Jiangsu Cancer Institute & Hospital 20
Early research (Phase 1)Study completedNCT05763004
What this trial is testing

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

Who this might be right for
Solid Tumor, Adult
ImmunOs Therapeutics AG 47
Testing effectiveness (Phase 2)Ended earlyNCT03595683
What this trial is testing

Pembrolizumab and EDP1503 in Advanced Melanoma

Who this might be right for
Melanoma (Skin)Melanoma
University of Chicago 8
Testing effectiveness (Phase 2)Ended earlyNCT04444141
What this trial is testing

PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma

Who this might be right for
Peripheral T-cell Lymphoma
Akeso 6
Testing effectiveness (Phase 2)Looking for participantsNCT06742502
What this trial is testing

Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL

Who this might be right for
Primary Mediastinal Diffuse Large B-cell Lymphoma
Sun Yat-sen University 30
Testing effectiveness (Phase 2)UnknownNCT05641493
What this trial is testing

A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation

Who this might be right for
Non Small Cell Lung Cancer
Shanghai Henlius Biotech 49
Testing effectiveness (Phase 2)UnknownNCT02632006
What this trial is testing

Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma

Who this might be right for
Advanced Hepatocellular Carcinoma
Second Military Medical University 40
Early research (Phase 1)Study completedNCT05788484
What this trial is testing

CDX-585 in Patients With Advanced Malignancies

Who this might be right for
Non-small Cell Lung CancerGastric CancerHead and Neck Cancer+11 more
Celldex Therapeutics 20
Testing effectiveness (Phase 2)Study completedNCT03123783
What this trial is testing

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Who this might be right for
CancerNon Small Cell Lung Cancer MetastaticMetastatic Melanoma+2 more
Apexigen America, Inc. 140
Testing effectiveness (Phase 2)UnknownNCT05816499
What this trial is testing

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
NSCLC Stage IVNSCLC Stage IIIBNSCLC Stage IIIC
Shanghai Chest Hospital 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT03921684
What this trial is testing

Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients

Who this might be right for
Rectal Cancer
Baruch Brenner 29
Testing effectiveness (Phase 2)UnknownNCT04524884
What this trial is testing

Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

Who this might be right for
Thyroid Cancer
Fudan University 10
Testing effectiveness (Phase 2)Ended earlyNCT02720484
What this trial is testing

Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer

Who this might be right for
Metastatic Carcinoma in the Adrenal CortexRecurrent Adrenal Cortex CarcinomaStage III Adrenal Cortex Carcinoma+1 more
Northwestern University 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06196814
What this trial is testing

AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC

Who this might be right for
Efficacy
Hunan Province Tumor Hospital 150
Large-scale testing (Phase 3)UnknownNCT06486220
What this trial is testing

PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized Clinical Trial.

Who this might be right for
Nasopharyngeal Carcinoma
Yun-fei Xia 96
Testing effectiveness (Phase 2)Ended earlyNCT04651127
What this trial is testing

Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer

Who this might be right for
Cervical CancerCervix CancerCervix Neoplasm
Sun Yat-sen University 5
Testing effectiveness (Phase 2)UnknownNCT03955354
What this trial is testing

PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma

Who this might be right for
Melanoma
Peking University Cancer Hospital & Institute 30
Next Page